MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
$435,344K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net income
Accrued expenses and other payab...
Share-based compensation expense...
Others
Negative Cash Flow Breakdown
Accounts receivable
Inventories
Amortization of research and dev...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
237,007
227,357
66,502
220,431
Depreciation and amortization expense
40,515
41,144
35,984
105,702
Share-based compensation expenses
137,405
123,355
123,761
387,096
Acquired in-process research and development
20,518
-
0
691
Amortization of research and development cost share liability
-29,518
-28,645
-26,251
-74,844
Impairment of equity investments
-
-
75,626
-
Loss on long-term investments
-
-
-596
-
Non-cash interest expense
-
-
14,872
-
Deferred income tax expense
-
-
9,469
-
Impairment of equity investments
-
-
-
34,216
Gain on bms termination settlement
-
-
0
-
Non-cash interest expense
-
21,096
-
-
Other items, net
8,240
6,172
-12,548
9,595
Accounts receivable
117,576
75,300
-2,340
167,294
Inventories
47,150
71,838
70,506
22,662
Other assets
11,377
-15,270
18,083
-55,247
Accounts payable
37,530
-42,187
87,214
-7,381
Accrued expenses and other payables
212,435
-16,819
145,876
165,886
Deferred revenue
-
-
1,293
-
Other liabilities
-4,113
1,731
15,418
3,550
Net cash provided by operating activities
462,820
201,336
417,347
710,233
Purchases of property, plant and equipment
27,476
40,789
37,522
148,317
Purchase of intangible assets
0
-
0
20,000
Purchase of long-term investments
-
-
11,834
-
Proceeds from sale or maturity of short-term investments
-
-
1,646
1,800
Proceeds from sale or maturity of investments
5,845
27
-
-
Purchase of in-process research and development
20,518
0
0
60,691
Other investing activities
7,204
4,748
-9,375
10,612
Net cash used in investing activities
-49,353
-45,510
-38,335
-237,820
Proceeds from sale of future royalties
-
-
26,000
885,000
Proceeds from long-term loan
-
-
850,586
0
Repayment of long-term loan
17,052
7,641
14,618
21,062
Proceeds from short-term loans
0
58,204
12,155
221,521
Repayment of short-term loans
0
0
768,999
275,782
Payments of debt issuance costs
-
-
23,392
-
Repayment of sale of future royalties liability
-1
2,557
4,044
-
Payments of withholding taxes from share-based awards
0
-
0
24,195
Proceeds from option exercises and employee share purchase plan
11,048
23,875
19,243
177,038
Other financing activities
-51
-3,249
0
0
Net cash provided by financing activities
-6,054
68,632
96,931
962,520
Effect of foreign exchange rate changes, net
19,836
19,320
23,162
36,862
Net increase in cash, cash equivalents, and restricted cash
427,249
243,778
499,105
1,471,795
Cash, cash equivalents, and restricted cash at beginning of period
4,853,425
4,609,647
4,110,542
2,638,747
Cash, cash equivalents, and restricted cash at end of period
5,280,674
4,853,425
4,609,647
4,110,542
Cash and cash equivalents
5,098,041
-
-
-
Short-term restricted cash
161,046
-
-
-
Long-term restricted cash
21,587
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income
$237,007K
Accrued expenses and
other payables
$212,435K
Share-based compensation
expenses
$137,405K
Depreciation and
amortization expense
$40,515K
Accounts payable
$37,530K
Acquired in-process
research and development
$20,518K
Net cash provided by
operating activities
$462,820K
Effect of foreign
exchange rate changes,...
$19,836K
Canceled cashflow
$209,734K
Net increase in
cash, cash...
$427,249K
Canceled cashflow
$55,407K
Accounts receivable
$117,576K
Inventories
$47,150K
Amortization of research and
development cost share...
-$29,518K
Other assets
$11,377K
Other liabilities
-$4,113K
Proceeds from sale or
maturity of investments
$5,845K
Proceeds from option
exercises and employee...
$11,048K
Repayment of sale of future
royalties liability
-$1K
Net cash used in
investing activities
-$49,353K
Net cash provided by
financing activities
-$6,054K
Canceled cashflow
$5,845K
Canceled cashflow
$11,049K
Purchases of property,
plant and equipment
$27,476K
Purchase of in-process
research and development
$20,518K
Other investing
activities
$7,204K
Repayment of long-term
loan
$17,052K
Other financing
activities
-$51K
Buy us a coffee
BeOne Medicines Ltd. (ONC)
BeOne Medicines Ltd. (ONC)